Dupilumab
度普利尤单抗IL-4Rα antibody whose 2026 NRDL payment scope expands from atopic dermatitis alone to 5 indications, adding prurigo nodularis, asthma, eosinophilic COPD, and bullous pemphigoid.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字SJ20200017
- Initial Approval Date
- Jun 17, 2020
- Notice Published
- Jun 19, 2020
- MAH
- Sanofi Winthrop Industrie (赛诺菲温特鲁普工业公司)
- Approved Scope
- Initial approval for adult moderate-to-severe atopic dermatitis; subsequently expanded across prurigo nodularis, asthma, eosinophilic COPD, and bullous pemphigoid.
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #104 · Class B
- Agreement Period
- 2027-01-01 to 2028-12-31
- Payment Standard
- * Confidential (marked with asterisk in NHSA PDF)
- 2026 Payment Scope
- Restricted to 5 indications: (1) Moderate-to-severe atopic dermatitis; (2) Adult moderate-to-severe prurigo nodularis; (3) Maintenance asthma in patients ≥6 years (type 2 inflammation with eosinophils ≥300/μL or OCS-dependent); (4) Uncontrolled eosinophilic COPD in adults (≥300/μL) on triple/dual therapy; (5) Adult bullous pemphigoid.
- 限:1.对传统治疗无效、有禁忌或不耐受的中重度特应性皮炎患者,需按说明书用药;2.治疗适合系统治疗的中度至重度结节性痒疹的成人患者;3.6岁及以上儿童和成人哮喘患者的维持治疗(伴有2型炎症嗜酸性粒细胞≥300个/μL或口服糖皮质激素依赖性);4.三联/二联治疗未控制的嗜酸性粒细胞升高(≥300个/μL)慢性阻塞性肺疾病(COPD)成人患者维持治疗;5.治疗大疱性类天疱疮的成人患者。
Commercial Insurance List
Not ListedNot listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.
2025 vs 2026 NRDL Payment Scope Comparison
Restricted to moderate-to-severe atopic dermatitis refractory, contraindicated, or intolerant to conventional therapy, per approved label.
限对传统治疗无效、有禁忌或不耐受的中重度特应性皮炎患者,需按说明书用药。
Restricted to 5 indications: (1) Moderate-to-severe atopic dermatitis; (2) Adult moderate-to-severe prurigo nodularis; (3) Maintenance asthma in patients ≥6 years (type 2 inflammation with eosinophils ≥300/μL or OCS-dependent); (4) Uncontrolled eosinophilic COPD in adults (≥300/μL) on triple/dual therapy; (5) Adult bullous pemphigoid.
限:1.对传统治疗无效、有禁忌或不耐受的中重度特应性皮炎患者,需按说明书用药;2.治疗适合系统治疗的中度至重度结节性痒疹的成人患者;3.6岁及以上儿童和成人哮喘患者的维持治疗(伴有2型炎症嗜酸性粒细胞≥300个/μL或口服糖皮质激素依赖性);4.三联/二联治疗未控制的嗜酸性粒细胞升高(≥300个/μL)慢性阻塞性肺疾病(COPD)成人患者维持治疗;5.治疗大疱性类天疱疮的成人患者。
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字SJ20200017 | Injection (注射液) 300mg (2ml) | Initial Approval Initial approval for adult moderate-to-severe atopic dermatitis; subsequently expanded across prurigo nodularis, asthma, eosinophilic COPD, and bullous pemphigoid. 首发获批用于外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎;后续陆续获批结节性痒疹、哮喘、COPD、大疱性类天疱疮等多项适应症。 | Approved: 2020-06-17 Published: 2020-06-19 | Sanofi Winthrop Industrie |
Change Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Payment Scope Updated
Expanded from 1 indication (atopic dermatitis) in 2025 (#93) to 5 indications in 2026 (#104): added prurigo nodularis, asthma (≥6y), eosinophilic COPD, and bullous pemphigoid.
Chinese original: 支付范围由2025版单一项(特应性皮炎)扩增至5项,新增结节性痒疹、6岁及以上哮喘、嗜酸性粒细胞升高COPD及大疱性类天疱疮。
NHSA · PDF p.126Verified 2026-11-20 - (2020-06-17)NMPA Approval· Notice published: Jun 19, 2020
NMPA Initial Marketing Approval (国药准字SJ20200017 · 300mg (2ml))
Initial approval for adult moderate-to-severe atopic dermatitis; subsequently expanded across prurigo nodularis, asthma, eosinophilic COPD, and bullous pemphigoid.
Chinese original: 首发获批用于外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎;后续陆续获批结节性痒疹、哮喘、COPD、大疱性类天疱疮等多项适应症。
NMPA · NMPA Registration SJ20200017Verified 2026-11-21
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NHSAPublished 2025-12-07国家基本医疗保险、生育保险和工伤保险药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件
- NMPA国家药品监督管理局政务服务门户与药品查询Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20